36 results on '"Malec, Lynn M."'
Search Results
2. HTRS2023.O6B.3 FVIII deficiency leads to lower atherogenic ApoB-lipoprotein and higher fibrinolysis
3. Bleeding patterns in patients before and after diagnosis of von Willebrand disease: Analysis of a US medical claims database
4. Emicizumab for the Treatment of Acquired Hemophilia a: A Multicenter US Case Series
5. Perioperative Outcomes Associated with Inhibitor Status in Patients with Hemophilia - a Retrospective Cohort Study
6. ATHN Transcends: A Natural History Cohort Study of the Safety, Effectiveness and Practice of Treatment in People with Non-Neoplastic Hematologic Disorders
7. Design of the INHIBIT trial: preventing inhibitors by avoiding ‘danger’, prolonging half-life and promoting tolerance
8. Hemophilia Natural History Study (ATHN 7): Baseline Characteristics, Adverse Events, and Self-Reported Health Status of Individuals with Hemophilia a and B
9. Inhibit Clinical Trials Platform to Prevent and Eradicate Inhibitors: Feasibility Survey of Current Prophylaxis and Immune Tolerance Practices
10. U.S. Cohort Study of Previously Untreated Patients with Congenital Hemophilia (ATHN 8: PUPs Study): Association between Family History and Age of Diagnosis
11. Observational study of recombinant factor VIII-Fc, rFVIIIFc, in hemophilia A
12. Bleeding patterns in patients before and after diagnosis of von Willebrand disease: Analysis of a US medical claims database.
13. The impact of extended half‐life factor concentrates on prophylaxis for severe hemophilia in the United States
14. Spontaneous bleeding and poor bleeding response with extended half‐life factor IX products: A survey of select US haemophilia treatment centres
15. Spontaneous Bleeding and Poor Bleeding Response with Extended Half-Life Factor IX Products: A Survey of Select US and Canadian Hemophilia Treatment Centers
16. Analysis of Bleeding and Treatment Patterns in Children and Adolescents before and after Von Willebrand Disease Diagnosis Using Data from a US Medical Claims Database
17. Von Willebrand Disease Minimize Menorrhagia (VWDMin) Trial
18. Regional variation and cost implications of prescribed extended half‐life factor concentrates among U.S. Haemophilia Treatment Centres for patients with moderate and severe haemophilia
19. Adoption of Prophylaxis in the United States in the Era of Extended Half-Life Factor Concentrates
20. Real World Use of Extended Half-Life Products and the Impact on Bleeding Events and Joint Health in the United States
21. Prophylactic rtPA in the Prevention of Line-associated Thrombosis and Infection in Short Bowel Syndrome
22. Feasibility of the Von Willebrand disease PREVENT trial
23. Venous thromboembolism in pediatric trauma patients: Ten-year experience and long-term follow-up in a tertiary care center
24. Von Willebrand Factor to Prevent Postpartum Hemorrhage
25. Durability of ITI Utilizing Rfviiifc
26. Validation Study of the Composite Score to Identify Von Willebrand Disease in Children
27. Immune Tolerance Induction Using Rfviiifc (Eloctate)
28. Von Willebrand Factor for Menorrhagia: A Survey and Literature Review
29. Regulatory T Cell Response to Factor VIII in Mothers of Children with Hemophilia Inhibitors
30. Thrombin Generation and Bleeding in Hemophilia Inhibitor Patients during Immune Tolerance Induction
31. Three Cost-utility Analyses of Screening for Intracranial Hemorrhage in Neonates With Hemophilia
32. Postpartum Hemorrhage In Women With Von Willebrand Disease and Other Bleeding Disorders
33. Validation Study Of The Composite Score To Identify Von Willebrand Disease in Children
34. Observational Study of Recombinant Factor-VIII-Fc, Eloctate, in Hemophilia Patients with and without Inhibitors
35. Copper Deficiency
36. Feasibility of the Von Willebrand disease PREVENT trial.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.